Thermo Fisher Scientific
The Innovation Powerhouse in Life Sciences
John Rontree, Senior Director of Vertical Marketing, Life Science, Chromatography and Mass SpectrometryJohn Rontree, Senior Director of Marketing, Thermo Fisher Scientific, when asked about the major challenges gnawing in the market today says, “With the massive growth in the biotherapeutic market, scientists are challenged with increasing analytical complexity due to the advent of potent monoclonal antibodies such as Antibody Drug Congugates and Bi-Specifics.
The company is a one-stop shop for multiple biological, bio-pharmaceutical companies, healthcare institutions, and other life sciences firms of all sizes around the globe
This requires us to build more sophisticated instrument platforms which we can build into workflow solutions to facilitate biologists in their decision making processes.”
Thermo Fisher Scientific, renowned as one of the biggest innovative forces in the domain, offers all products that a client might need along the entire bio-production chain, addressing the specialized requirements of both complex research and rugged QA-QC testing. Rontree specifically highlights the company’s efforts in two key disruptive technologies for the industry today—mass spectrometry and chromatography. While chromatography is a fundamental tool for domain analysts to separate biomolecules for deeper inspection, mass spectrometry has been one of the most promising and widely-adopted techniques in dealing with complex biomolecule characterizations. Thermo Fisher Scientific has made these technologies seamlessly adaptable to both advanced research and QA-QC environments, while greatly enhancing the technologies’ productivity, efficiency, and ROI performance.
For Rontree, data and cloud, will play a significant role for Thermo Fisher Scientific in the near future. The company focuses on more innovative life sciences products in association with cloud-data technologies to deepen information analysis, build better workflows for the industry, and deliver meaningful decisions in drugs production and healthcare.
Thermo Fisher Scientific News
Thermo Fisher Scientific Introduces Revolutionary S/TEM Platform
Thermo Fisher Scientific Showcases Advanced Analytical Solutions, Software and Scientific Insights at DIOXIN 2019
KYOTO, JAPAN: Thermo Fisher Scientific is showcasing its comprehensive collection of advanced gas chromatography mass spectrometry (GC-MS) solutions for the validated quantification of dioxins and other persistent organic pollutants (POPs) in food and feed during the 39th International Symposium on Halogenated Persistent Organic Pollutants (DIOXIN 2019), being held August 25–30, at Booth #P1 in the Kyoto International Conference Center, Kyoto, Japan.
Food safety laboratories can use the new Thermo Scientific Dioxin Analyzer to meet evolving regulatory expectations for the confirmatory analysis of dioxins and other POPs. The new comprehensive GC-MSbased analytical workflow brings together the Thermo Scientific Triple Quadrupole TSQ 9000 GC-MS/MS system with the Thermo Scientific Advanced Electron Ionization (AEI) source, capillary GC column, system suitability check, standard solutions, software and comprehensive user guidelines for reliable and costeffective assessment of food and feed for dioxins and POPs.
Enhancing productivity and throughput while sustaining sensitivity and performance, the new Thermo Scientific DFS Software Package for the Thermo Scientific DFS Magnetic Sector GC-HRMS provides food safety laboratories with a fully automated solution for the quantitative analysis of dioxins and other POPs in various matrices. The DFS Software Package enables the automation of daily instrument operations, enhancing ease-of-use with calculation transparency for full data confidence.
“Food testing laboratories are at the frontline of the global food chain and must screen food and feed for an array of contaminants to monitor its integrity and safeguard consumers – but this presents significant analytical and resource challenges,” said Khalil Divan, senior director, marketing, food and beverage, Thermo Fisher Scientific. “The launch of the Dioxin Analyzer and the DFS Software Package for the DFS Magnetic Sector GC-HRMS demonstrates our continued commitment to help customers protect the integrity of the global food chain by providing access to advanced, analytical solutions that meets their individual requirements for the accurate quantification of dioxins and other POPs within any food or feed sample matrix.”
Alongside the collection of GC-MS solutions, Thermo Fisher is hosting a seminar series with company and industry experts. The seminars will highlight how the latest developments in chromatography and mass spectrometry are enhancing the quantitation of dioxins and other POPs within the routine laboratory environment.
Food safety laboratories can use the new Thermo Scientific Dioxin Analyzer to meet evolving regulatory expectations for the confirmatory analysis of dioxins and other POPs. The new comprehensive GC-MSbased analytical workflow brings together the Thermo Scientific Triple Quadrupole TSQ 9000 GC-MS/MS system with the Thermo Scientific Advanced Electron Ionization (AEI) source, capillary GC column, system suitability check, standard solutions, software and comprehensive user guidelines for reliable and costeffective assessment of food and feed for dioxins and POPs.
Enhancing productivity and throughput while sustaining sensitivity and performance, the new Thermo Scientific DFS Software Package for the Thermo Scientific DFS Magnetic Sector GC-HRMS provides food safety laboratories with a fully automated solution for the quantitative analysis of dioxins and other POPs in various matrices. The DFS Software Package enables the automation of daily instrument operations, enhancing ease-of-use with calculation transparency for full data confidence.
“Food testing laboratories are at the frontline of the global food chain and must screen food and feed for an array of contaminants to monitor its integrity and safeguard consumers – but this presents significant analytical and resource challenges,” said Khalil Divan, senior director, marketing, food and beverage, Thermo Fisher Scientific. “The launch of the Dioxin Analyzer and the DFS Software Package for the DFS Magnetic Sector GC-HRMS demonstrates our continued commitment to help customers protect the integrity of the global food chain by providing access to advanced, analytical solutions that meets their individual requirements for the accurate quantification of dioxins and other POPs within any food or feed sample matrix.”
Alongside the collection of GC-MS solutions, Thermo Fisher is hosting a seminar series with company and industry experts. The seminars will highlight how the latest developments in chromatography and mass spectrometry are enhancing the quantitation of dioxins and other POPs within the routine laboratory environment.
Industry-Leading Product, Compliance and Services Offering Facilitates cGMP-Compatible Cell and Gene Therapy Manufacturing
Waltham, MA - Thermo Fisher Scientific announces the launch of an industry-leading product, compliance and services portfolio, compatible with current Good Manufacturing Practice (cGMP) and designed to enable rapid start-up of clinical and commercial cell and gene therapy manufacturing.
Developed as the first-ever all-inclusive solution to simplify and optimize the cGMP equipment installation and validation process, the Thermo Scientific Cell Therapy Systems (CTS) Series Laboratory Equipment are comprised of a comprehensive range of key laboratory equipment routinely used in cell and gene therapy manufacturing, including biological safety cabinets, centrifuges, CO2 incubators and cold storage systems. Each product includes a factory acceptance test documentation package comprised of operating certificates, performance specifications, user guides and technical manuals. The portfolio is also supported by high quality field compliance services, including installation setup, IQ, OQ and other support, such as temperature mapping and calibration.
"Cell and gene therapy manufacturers are under increasing pressure to deliver new life-saving therapies, while challenged with complex manufacturing processes and the associated compliance requirements," said Hugh Tansey, senior director, innovation and growth programs for laboratory equipment at Thermo Fisher Scientific. "In support of cGMP, the CTS Series Laboratory Equipment have been developed to address some of the challenges our customers face every day so they can focus on what matters the most ” using science to save patient lives."
The CTS Series Laboratory Equipment are manufactured at ISO13485-certified sites, and designed to meet global mechanical and electrical safety standards. The portfolio is available for sale in more than 150 countries and is supported by an extensive global service network of subject matter specialists.
Developed as the first-ever all-inclusive solution to simplify and optimize the cGMP equipment installation and validation process, the Thermo Scientific Cell Therapy Systems (CTS) Series Laboratory Equipment are comprised of a comprehensive range of key laboratory equipment routinely used in cell and gene therapy manufacturing, including biological safety cabinets, centrifuges, CO2 incubators and cold storage systems. Each product includes a factory acceptance test documentation package comprised of operating certificates, performance specifications, user guides and technical manuals. The portfolio is also supported by high quality field compliance services, including installation setup, IQ, OQ and other support, such as temperature mapping and calibration.
"Cell and gene therapy manufacturers are under increasing pressure to deliver new life-saving therapies, while challenged with complex manufacturing processes and the associated compliance requirements," said Hugh Tansey, senior director, innovation and growth programs for laboratory equipment at Thermo Fisher Scientific. "In support of cGMP, the CTS Series Laboratory Equipment have been developed to address some of the challenges our customers face every day so they can focus on what matters the most ” using science to save patient lives."
The CTS Series Laboratory Equipment are manufactured at ISO13485-certified sites, and designed to meet global mechanical and electrical safety standards. The portfolio is available for sale in more than 150 countries and is supported by an extensive global service network of subject matter specialists.
Thermo Fisher Scientific Completes Acquisition of The Binding Site Group
Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma
Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment
WALTHAM, Mass- Thermo Fisher Scientific Inc. (NYSE: TMO) announced that it has completed its acquisition of The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates. Thermo Fisher announced the agreement to acquire The Binding Site on October 31, 2022.
“We are very excited to welcome The Binding Site colleagues to Thermo Fisher Scientific,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “The Binding Site expands our existing specialty diagnostics portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. Early diagnosis and well-informed treatment decisions can make a significant difference in patient outcomes, and we are excited by the opportunity to enable further advancements in this area for the benefit of patients.”
The Binding Site has more than 1,200 employees globally and will become part of Thermo Fisher's Specialty Diagnostics segment.
Serving clinicians and laboratory professionals worldwide, The Binding Site provides specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The Binding Site’s Freelite® offering is widely recommended for multiple myeloma diagnosis and monitoring across all stages of the disease by major clinical guideline publications.
The transaction is expected to be accretive to adjusted earnings per share by $0.07 in 2023.1
Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment
WALTHAM, Mass- Thermo Fisher Scientific Inc. (NYSE: TMO) announced that it has completed its acquisition of The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.3 billion, or $2.8 billion at current exchange rates. Thermo Fisher announced the agreement to acquire The Binding Site on October 31, 2022.
“We are very excited to welcome The Binding Site colleagues to Thermo Fisher Scientific,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “The Binding Site expands our existing specialty diagnostics portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. Early diagnosis and well-informed treatment decisions can make a significant difference in patient outcomes, and we are excited by the opportunity to enable further advancements in this area for the benefit of patients.”
The Binding Site has more than 1,200 employees globally and will become part of Thermo Fisher's Specialty Diagnostics segment.
Serving clinicians and laboratory professionals worldwide, The Binding Site provides specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The Binding Site’s Freelite® offering is widely recommended for multiple myeloma diagnosis and monitoring across all stages of the disease by major clinical guideline publications.
The transaction is expected to be accretive to adjusted earnings per share by $0.07 in 2023.1
Producing the right materials and making the right design choices are critical to solving challenges such as developing safer and longer lasting batteries, creating lighter materials for improved energy efficiency, and building faster, higher capacity computer processors or memory devices. Spectra is ideal for researchers in academic or industrial labs who need to characterize a wide variety of materials at the atomic level. It allows them to create lightweight materials such as advanced steels, aluminum alloys or plastics used to develop safer or more fuel-efficient transportation. Spectra also supports research for new semiconductor structures and materials, which delivers the essential building blocks for future generations of higher performance electronic devices.
"Thermo Fisher Scientific has a long history of leadership in high-end transmission electron microscopes, and Spectra continues this direction by delivering the best commercially available atomic-level S/TEM imaging and analysis in a single tool," said Mike Shafer, president of materials and structural analysis at Thermo Fisher Scientific. "Spectra offers unprecedented ease-of-use for the widest range of applications while solving some of today's most challenging problems, including the analysis of beam-sensitive and increasingly complex materials and the imaging of shrinking semiconductor devices."
Spectra includes revolutionary detection capabilities, allowing scientists and engineers to acquire previously hard to obtain atomic-level data for a wider range of applications. The platform makes it possible to obtain detailed images of extremely beam-sensitive materials and semiconductor structures including metal organic frameworks, zeolites and polymers that can be damaged or destroyed if exposed to the electron beam for too long or at the wrong voltage. It also meets the growing demand for high-volumes of atomic-level chemical analysis using several modalities such as EDX (Energy Dispersive X-Ray) or EELS (Electron Energy Loss Spectroscopy).
The platform includes several new features that take S/TEM microscopy to the next level, including:
•A higher-brightness electron source: An exceptionally bright cold field emission gun (X-CFEG) is a new technology offering higher contrast imaging. For chemical analysis and x-ray analytics, it provides more than twice the signal and greater than ten percent higher spatial resolution than conventional CFEG sources found in current generation TEMs. The result is higher quality imaging and analysis at a higher resolution, allowing users to examine a wider range of materials.
•Easier analysis of electrical properties: The new X-FEG/Ultimono source allows researchers and engineers to generate complex high energy resolution data in parallel rather than dedicating a separate tool for that single purpose. This helps accelerate new materials development because researchers will better understand the electrical behavior parallel to other critical properties.
•High dynamic range mapping: The Electron Microscope Pixel Array Detector (EMPAD) is a high-speed pixelated STEM detector that allows researchers to perform a large number of advanced applications such as Ptychography for super-high resolution and user segmentation of signals. This helps unravel more properties critical for the development of new materials and processes.
Spectra 300 includes three source options, an XFEG Mono, X-FEG UltiMono and an X-CFEG and is designed for ultimate atomic-level imaging and analysis on the widest variety of samples. Spectra 200 offers a 200 kV C-FEG and is ideal for high-contrast imaging and chemical analysis.